SRZN

Surrozen, Inc./DE

7 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bearishMay 6

Reported a net loss of $127.5 million driven by non-cash liability adjustments.

earnings miss

70%

bullishMay 6

Raised $26.9 million through an ATM program during the quarter.

capital raise

60%

bearishMay 6

R&D expenses increased 42% year-over-year to $9.3 million.

margin compression

40%

bearishMay 6

Reported a net loss of $127.5 million driven by non-cash liability adjustments.

earnings miss

70%

bullishMay 6

Raised $26.9 million through an ATM program during the quarter.

capital raise

60%

bearishMay 6

R&D expenses increased 42% year-over-year to $9.3 million.

margin compression

40%

bearishMay 6

Reported a net loss of $127.5 million driven by non-cash liability adjustments.

earnings miss

70%

bullishMay 6

Raised $26.9 million through an ATM program during the quarter.

capital raise

60%

bearishMay 6

R&D expenses increased 42% year-over-year to $9.3 million.

margin compression

40%

bearishMay 6

Reported a net loss of $127.5 million driven by non-cash liability adjustments.

earnings miss

70%

bullishMay 6

Raised $26.9 million through an ATM program during the quarter.

capital raise

60%

bearishMay 6

R&D expenses increased 42% year-over-year to $9.3 million.

margin compression

40%

bearishMay 6

Reported a net loss of $127.5 million driven by non-cash liability adjustments.

earnings miss

70%

bullishMay 6

Raised $26.9 million through an ATM program during the quarter.

capital raise

60%

bearishMay 6

R&D expenses increased 42% year-over-year to $9.3 million.

margin compression

40%

bearishMay 6

Reported a net loss of $127.5 million driven by non-cash liability adjustments.

earnings miss

70%

bullishMay 6

Raised $26.9 million through an ATM program during the quarter.

capital raise

60%

bearishMay 6

R&D expenses increased 42% year-over-year to $9.3 million.

margin compression

40%

bearishMay 6

Reported a net loss of $127.5 million driven by non-cash liability adjustments.

earnings miss

70%

bullishMay 6

Raised $26.9 million through an ATM program during the quarter.

capital raise

60%

bearishMay 6

R&D expenses increased 42% year-over-year to $9.3 million.

margin compression

40%

Filing History

10-QMay 6, 2026

The Q1 2026 filing reveals a company at a critical crossroads, where technical validation is clashing with financial volatility. The receipt of the Boehringer Ingelheim milestone payment proves that Surrozen's Wnt-modulating platform has commercial utility, but the massive non-cash losses highlight the complex and risky nature of its financing structures. The company has effectively traded long-term stability for a high-stakes binary outcome centered on the SZN-8141 IND filing. Investors are now faced with a clear trade-off: the potential for a massive value inflection point upon FDA clearance versus the risk of a liquidity crisis should that clearance be delayed. While the current cash position provides a 12-month cushion, the structural dependence on the contingent PIPE tranche means that the company's valuation is now inextricably linked to regulatory timelines rather than just scientific merit. Ultimately, the filing suggests that Surrozen is executing its scientific roadmap effectively, but its financial architecture remains aggressive. The next six months will be decisive, as the market watches for the SZN-8141 IND submission and the subsequent unlocking of nearly $100 million in capital.